Moderna's melanoma vaccine plus Keytruda cut the risk of recurrence or death by 42% in Phase 3, yet the stock sank. Here's ...
One of these mRNA pioneers has the products and pipeline to drive growth.
A setback would barely affect Moderna's sales because the cancer vaccine is not yet approved. The company still generates ...
The healthcare stock has hit multi-year highs this year amid positive results from its personalized cancer vaccine.
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
The drop is a sharp reversal of a massive 2026 stock rally fueled by optimism over its personalized cancer vaccine.
Moderna stock has skyrocketed this year.
Key TakeawaysModerna stock fell 17% in the past week after guiding to about $4 billion of cash costs in 2027 and up to $4. 5 ...
One stock has soared more than sevenfold this year, another just lost a quarter of its value on leaked data, and a third carries the fate of millions of retirees.
Initial Phase 1/2 data highlight the potential of Moderna's multiplexed mRNA approach in relapsed or refractory ...
Even after its latest sharp fall, the drugmaker’s stock price assumes wild successes.
WHO Technical Advisory Group recommends mRNA-1469 for inclusion in efficacy study following encouraging Phase 1 ...